Cheryl M. Koh
Silicon Therapeutics (United States)(US)APA Corporation (United States)
Publications by Year
Research Areas
RNA modifications and cancer, Cancer-related gene regulation, Epigenetics and DNA Methylation, Prostate Cancer Treatment and Research, interferon and immune responses
Most-Cited Works
- → NOTCH Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts(2009)642 cited
- → Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis(2008)442 cited
- → MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis(2015)385 cited
- → Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation(2019)276 cited
- → Cell-Type Independent MYC Target Genes Reveal a Primordial Signature Involved in Biomass Accumulation(2011)170 cited
- → Myc Enforces Overexpression ofEZH2in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms(2011)169 cited
- → Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth(2015)165 cited
- → GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification(2016)163 cited
- → Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity(2015)159 cited
- → Alterations in Nucleolar Structure and Gene Expression Programs in Prostatic Neoplasia Are Driven by the MYC Oncogene(2011)138 cited